- Home
- PEB vs ARVN Comparison
PEB vs ARVN Comparison
Compare PEB & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PEB | ARVN |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 806.0M |
| IPO Year | 2009 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PEB | ARVN |
|---|---|---|
| Price | $11.30 | $12.61 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 23 |
| Target Price | $12.28 | ★ $17.80 |
| AVG Volume (30 Days) | 2.0M | ★ 2.3M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,464,126,000.00 | $312,300,000.00 |
| Revenue This Year | $2.32 | $11.06 |
| Revenue Next Year | $2.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.99 | ★ 93.86 |
| 52 Week Low | $7.42 | $5.90 |
| 52 Week High | $14.85 | $22.48 |
Technical Indicators
Market Signals| Indicator | PEB | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 56.64 | 58.46 |
| Support Level | $10.67 | $12.47 |
| Resistance Level | $11.71 | $13.56 |
| Average True Range (ATR) | 0.34 | 0.54 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 61.24 | 54.68 |
Price Performance
Historical ComparisonAbout PEB Pebblebrook Hotel Trust of Beneficial Interest
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.